The Swiss biotech penned a CHF 127.5 million ($138 million) deal for the human neutrophil elastase inhibitor to expand its clinical pipeline.
Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
The Bill & Melinda Gates Foundation has teamed up with big pharma Novartis and its experimental drug for certain diarrheal diseases.
Bristol-Myers will use Sirenas' drug discovery platform to identify compounds for a range of "challenging" targets.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.
Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Theravance will bring its GI drug through phase 2/3 in Crohn's disease and ulcerative colitis.
Celltex Therapeutics and Texas A&M Institute for Regenerative Medicine hope to have a stem cell-derived therapy for Alzheimer’s within three years.